Jefferies Initiates Coverage On Haemonetics with Buy Rating, Announces Price Target of $150
HAE Q3 CY2026 deep dive: plasma growth and new product launches drive momentum
International Markets and Haemonetics (HAE): A Deep Dive for Investors
Should Raised Revenue Outlook Require Action From Haemonetics Stock Investors?
Haemonetics (HAE) Stock May Be 34% Undervalued On Cash Flow
Haemonetics Q2 Earnings Call Highlights
Haemonetics (HAE) Beats Q2 Expectations, Is The Stock Still Cheap?
Citigroup Maintains Buy on Haemonetics, Raises Price Target to $149
Barrington Research Maintains Outperform on Haemonetics, Raises Price Target to $145
Haemonetics Corp (HAE) (Q2 2027) Earnings Call Highlights: Raised Guidance and Expanded CSL ...
Haemonetics Corporation Q2 2027 Earnings Call Summary
Haemonetics (HAE) Q2 2027 Earnings Call Transcript
Haemonetics Corporation 2027 Q2 - Results - Earnings Call Presentation
BTIG Maintains Buy on Haemonetics, Raises Price Target to $142
Haemonetics Corporation (HAE) Q2 2027 Earnings Call Transcript
Haemonetics Corporation Reports Second Quarter Fiscal 2027 Revenue of $357.8 million
Haemonetics (NYSE:HAE) delivers strong Q3 CY2026 numbers
Haemonetics: Fiscal Q2 Earnings Snapshot
Haemonetics (HAE) Q2 Earnings and Revenues Surpass Estimates
Haemonetics Corporation Announces Second Quarter Fiscal 2027 Financial Results Available on Investor Relations Website
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.